Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Diseases 1

Interventions

Brentuximab Vedotin 7dacetuzumab 4Lenalidomide 3Doxorubicin 3Dexamethasone 3spartalizumab 2lintuzumab 2fludarabine 2Vincristine 2Rituximab 2Rifampin 2Prednisone 2Gemcitabine 2Cyclophosphamide 2tanespimycin 1sabatolimab 1pomalidomide 1pirtobrutinib 1fludarabine phosphate 1ficlatuzumab 1daratumumab 1Vinblastine 1Thiotepa 1TAS4464 1Sertraline 1R-CHOP protocol 1Pam2CSK4 acetate and ODN M362 combination 1Midazolam 1Melphalan 1LCL161 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Diseases × TAS4464 × Clear all
NCT02978235 2024-09-05

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Taiho Oncology, Inc.

Phase 1 Terminated
11 enrolled
LymphoidPlasma cell

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡